News

Yale pharmacology professor Barbara Ehrlich and her team have uncovered a mechanism driving a rare, lethal disease called Wolfram Syndrome and also a potential treatment.

A new study examines the catalytic activity of PrimPol and effects of HIV+ patients on tenofovir-based Anti-Retroviral Therapy (ART) with mitochondrial toxicity.

The new research provides insight into the lungs’ cellular landscape, shows how IPF affects lung cells, and suggests both a possible explanation for patients’ breathing difficulties and potential new avenues for treatment.

Across Yale Cancer Center this spring, most research labs shut down to protect their personnel from COVID-19. To protect patients, clinical trial enrollment also took a two month pause. But several of our researchers with relevant expertise have continued to conduct critical research on SARS-CoV-2, the deadly new coronavirus that causes COVID-19.

Three pilot projects to investigate aspects of the current pandemic have received funding from Yale’s COVID-19 Research Resource Fund, which was built with generous contributions from Yale’s donors.

Yale researchers have discovered a “jamming signal” that blocks a powerful immune system stimulant called interleukin-18 (IL-18) from reaching tumors, including in cancers that are resistant to conventional immunotherapy treatments, they report June 24 in the journal Nature.

The donation will fund the laboratories of at least six scientists on the Yale School of Medicine faculty, for work on vaccine development to prevent future outbreaks as well as treatments for people who are already infected.

Women's Health Research at Yale has launched a study to uncover sex-specific differences in immune response to SARS-CoV-2, the virus which causes COVID-19.

Marina Picciotto, PhD, Charles B.G. Murphy Professor of Psychiatry and Professor in the Child Study Center, of Neuroscience and of Pharmacology, has been named the 2020 recipient of the Carnegie Prize in Mind and Brain Sciences.